BR112021006280A2 - terapias imunoablativas - Google Patents

terapias imunoablativas

Info

Publication number
BR112021006280A2
BR112021006280A2 BR112021006280A BR112021006280A BR112021006280A2 BR 112021006280 A2 BR112021006280 A2 BR 112021006280A2 BR 112021006280 A BR112021006280 A BR 112021006280A BR 112021006280 A BR112021006280 A BR 112021006280A BR 112021006280 A2 BR112021006280 A2 BR 112021006280A2
Authority
BR
Brazil
Prior art keywords
immunoablative
therapies
diseases
compositions
immunoablation
Prior art date
Application number
BR112021006280A
Other languages
English (en)
Inventor
Deisher Theresa
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of BR112021006280A2 publication Critical patent/BR112021006280A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)

Abstract

terapias imunoablativas. esta invenção pertence a composições farmacêuticas compreendendo um glicocorticoide para uso no tratamento de doenças por imunoablação. as composições da invenção podem ser para uso no tratamento de doenças que são mediadas por células imunes como os linfócitos.
BR112021006280A 2018-10-03 2019-10-03 terapias imunoablativas BR112021006280A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18198491.5A EP3488851A1 (en) 2018-10-03 2018-10-03 Immunoablative therapies
PCT/US2019/054395 WO2020072713A1 (en) 2018-10-03 2019-10-03 Immunoablative therapies

Publications (1)

Publication Number Publication Date
BR112021006280A2 true BR112021006280A2 (pt) 2021-07-06

Family

ID=63762311

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021006280A BR112021006280A2 (pt) 2018-10-03 2019-10-03 terapias imunoablativas

Country Status (14)

Country Link
US (2) US11446314B2 (pt)
EP (2) EP3488851A1 (pt)
JP (1) JP2020059703A (pt)
KR (1) KR20210072039A (pt)
CN (1) CN113164497A (pt)
AU (1) AU2019355004A1 (pt)
BR (1) BR112021006280A2 (pt)
CA (1) CA3113969A1 (pt)
EA (1) EA202190927A1 (pt)
ES (1) ES2863369T3 (pt)
MX (1) MX2021003797A (pt)
SG (1) SG11202103031SA (pt)
WO (1) WO2020072713A1 (pt)
ZA (1) ZA202102727B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3118505A1 (en) * 2018-11-14 2020-05-22 Avm Biotechnology, Llc Stable glucocorticoid formulation
CA3168378A1 (en) * 2020-02-28 2021-09-02 Avm Biotechnology, Llc Lypmphocyte population and methods for producing same
JP2023524434A (ja) 2020-04-29 2023-06-12 エーブイエム・バイオテクノロジー・エルエルシー 新規療法
KR20230018422A (ko) * 2020-06-01 2023-02-07 에이브이엠 바이오테크놀로지, 엘엘씨 Icam-조절제를 이용한 치료 방법
KR20220163638A (ko) 2021-06-03 2022-12-12 현대모비스 주식회사 차량용 제동장치 및 그 제어방법
IL311041A (en) 2021-09-01 2024-04-01 Avm Biotechnology Llc Lymphocyte population and methods for their production

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3368937A (en) * 1965-01-26 1968-02-13 Merck & Co Inc Injectable solid steroid-anesthetic
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
AU2003225793A1 (en) 2002-03-15 2003-09-29 Baxter Healthcare S.A. Methods and compositions for directing cells to target organs
CA2484989A1 (en) * 2002-05-02 2003-11-27 The Washington University Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency
AU2003230266B2 (en) * 2002-05-08 2008-03-13 Btu International, Inc. Plasma catalyst
NZ572388A (en) 2002-05-17 2010-05-28 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
JP3968334B2 (ja) 2002-09-11 2007-08-29 株式会社日立ハイテクノロジーズ 荷電粒子線装置及び荷電粒子線照射方法
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20040247574A1 (en) 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
PL1835924T3 (pl) 2004-12-23 2014-01-31 Ethicon Incorporated Leczenie choroby Parkinsona i zaburzeń związanych z tą chorobą z użyciem komórek uzyskiwanych po porodzie
RU2468797C2 (ru) * 2005-06-09 2012-12-10 Биолипокс Аб Способ и композиция для лечения воспалительных нарушений
JP4997239B2 (ja) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体およびその使用方法
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
US20100247491A1 (en) 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
WO2009152186A1 (en) 2008-06-09 2009-12-17 American Stem Cell, Inc. Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
ES2627043T3 (es) 2008-06-09 2017-07-26 Targazyme, Inc. Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
JP6096116B2 (ja) 2010-08-18 2017-03-15 デイシャー、テレサ リンパ組織に幹細胞および前駆細胞が結合することを阻害する組成および方法、ならびにリンパ組織の胚中心を再生させるための組成および方法。
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
EA201391059A1 (ru) 2011-01-18 2014-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции для лечения рака и способы их применения
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
AU2012308205A1 (en) 2011-09-16 2014-03-13 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
US20130287747A1 (en) 2012-04-30 2013-10-31 Allocure, Inc. Methods of Treating Acute Kidney Injury Using Mesenchymal Stem Cells
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US11091543B2 (en) * 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
KR20220008388A (ko) 2015-05-28 2022-01-20 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
WO2018153984A1 (en) * 2017-02-23 2018-08-30 Universität Bern Mtor inhibitor-corticoid combination therapy for multiple sclerosis
CA3054443A1 (en) 2017-04-01 2018-10-14 Avm Biotechnology, Llc Replacement of cytotoxic preconditioning before cellular immunotherapy

Also Published As

Publication number Publication date
US20210338689A1 (en) 2021-11-04
AU2019355004A1 (en) 2021-05-06
US11446314B2 (en) 2022-09-20
CN113164497A (zh) 2021-07-23
JP2020059703A (ja) 2020-04-16
CA3113969A1 (en) 2020-04-09
EA202190927A1 (ru) 2021-08-02
ZA202102727B (en) 2022-05-25
EP3488851A1 (en) 2019-05-29
MX2021003797A (es) 2021-08-11
US20200108078A1 (en) 2020-04-09
EP3860612A1 (en) 2021-08-11
WO2020072713A1 (en) 2020-04-09
SG11202103031SA (en) 2021-04-29
KR20210072039A (ko) 2021-06-16
ES2863369T3 (es) 2021-10-11

Similar Documents

Publication Publication Date Title
BR112021006280A2 (pt) terapias imunoablativas
CO2019002371A2 (es) Adenovirus armado con captador biespecífico de linfocitos t (bite)
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CO2017011851A2 (es) Compuestos novedosos
BR112018067679A2 (pt) células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
MX2019003091A (es) Inhibidores de la interaccion de menina-mll.
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
CO2019012080A2 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
BR112017025529A2 (pt) agentes de ligação ao tigit e usos destes
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112017026704A2 (pt) uso
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
UY36021A (es) Proteìnas fc multimèricas
EA201692109A1 (ru) Варианты антител к фактору d и их применение
BR112018011228A2 (pt) tratamentos de combinação e seus usos e métodos
AR120223A1 (es) Proteínas que unen nkg2d, cd16 y flt3
CL2018001742A1 (es) Compuestos indolinones y sus usos en el tratamiento de enfermedades fibroticas.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7